Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone for bipolar disorders.

Martha Sajatovic1, Subramoniam Madhusoodanan, Matthew A Fuller

  • 1Department of Psychiatry, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Martha.sajatovic@uhhs.com

Expert Review of Neurotherapeutics
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the inter-relationships among depression, anxiety and somatic symptoms in haemodialysis patients: a cross-sectional structural equation modelling study.

BMJ open·2026
Same author

Qualitative Experience with an Adherence Promotion Intervention Among Individuals with Bipolar Disorder: What Is Helpful and Unhelpful?

Medicina (Kaunas, Lithuania)·2026
Same author

Geographic Disparities in People with Epilepsy: Differences in Self-Efficacy and Quality of Life.

Journal of epilepsy research·2026
Same author

Depression and associated factors among primary school adolescents with hearing impairment in Kampala district, Uganda: A cross-sectional study.

PLOS mental health·2026
Same author

The TargetEd MAnageMent Intervention for Reducing Stroke Risk in Black Men: A 6-Month Prospective Randomized Controlled Trial.

International journal of aging & human development·2026
Same author

Clinical and Sociodemographic Correlates of Poor Medication Adherence in People With Bipolar Disorder: A Systematic Review and Meta-Analysis.

Bipolar disorders·2026
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Risperidone offers a new option for treating bipolar disorder, showing efficacy and tolerability in manic episodes. This atypical antipsychotic is approved for acute manic or mixed episodes, with potential for longer-term use.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Atypical antipsychotics are increasingly used for bipolar disorder.
  • Risperidone is a key medication in this class.

Purpose of the Study:

  • To provide a comprehensive drug profile of risperidone for bipolar disorder.
  • To review clinical trials, safety, and regulatory aspects of risperidone in bipolar disorder treatment.

Main Methods:

  • Review of controlled and open-label treatment trials.
  • Analysis of postmarketing surveillance data.
  • Examination of risperidone's chemistry, pharmacodynamics, pharmacokinetics, and metabolism.

Main Results:

  • Risperidone demonstrates efficacy and tolerability in the manic phase of bipolar disorder.

Related Experiment Videos

  • Approved for short-term treatment of acute manic/mixed episodes as monotherapy or combination therapy.
  • Evidence suggests potential utility in longer-term bipolar disorder management.

    • Conclusions:

    • Risperidone is an important treatment option for bipolar mania.
    • Further research may explore its role in long-term bipolar disorder management.
    • Comprehensive understanding of risperidone's profile is crucial for optimal patient outcomes.